MarketCapExport financials
Coherus BioSciences (CHRS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Coherus BioSciences Balance Sheet 2025-2011 | CHRS
Brief overview of Coherus BioSciences's balance sheet strength
The review uses the five latest available annual reports between 2021 and 2025.
Assets fell from $679.3 million to $258.3 million. This may reflect either deliberate optimization or a reduction in business scale.
Assets and liabilities changed at similar rates, -62% and -66.1%. The funding mix did not shift sharply.
The equity ratio equals 23.6%, with a starting level of 14.4%. Stable cash flow is important under this structure.
Net debt moved below zero to -$85.6 million, reflecting surplus cash over debt.
The cash share moved from 61.4% to 34.4%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -$1.4 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Coherus BioSciences's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Coherus BioSciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-85.6 M | -121 M | -101 M | -59 M | -414 M | -135 M | 11 M | 30.7 M | -25.1 M | -23.8 M | -158 M | -150 M | -35.4 M | -12.8 M | - |
Long Term Debt |
1.46 M | 3.29 M | 351 K | 1.42 M | 498 K | 404 M | 178 M | 103 M | 102 M | 100 M | - | - | - | - | - |
Long Term Debt Current |
1.83 M | 1.69 M | 1.42 M | 3.13 M | 2.75 M | 2.57 M | 2.2 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 189 M | 105 M | 104 M | 103 M | 113 M | 68.7 M | 36.1 M | 6.09 M | - |
Total Current Liabilities |
140 M | 283 M | 332 M | 139 M | 165 M | 146 M | 115 M | 33.3 M | 28.4 M | 56.4 M | 106 M | 51.8 M | - | - | - |
Total Liabilities |
197 M | 581 M | 823 M | 618 M | 582 M | 561 M | 304 M | 138 M | 132 M | 159 M | 219 M | 120 M | 89.8 M | 17.3 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 1.96 M | 51 M | 24 M | 14.3 M | 2.02 M | - |
Retained Earnings |
-1.38 B | -1.55 B | -1.58 B | -1.34 B | -1.05 B | -763 M | -895 M | -985 M | -775 M | -537 M | -410 M | -187 M | -99.6 M | -46 M | - |
Total Assets |
258 M | 449 M | 630 M | 481 M | 679 M | 842 M | 409 M | 99.5 M | 163 M | 178 M | 212 M | 187 M | 47.4 M | 26.5 M | - |
Cash and Cash Equivalents |
88.9 M | 126 M | 103 M | 63.5 M | 417 M | 541 M | 178 M | 72.4 M | 127 M | 125 M | 158 M | 150 M | 39.6 M | 14.5 M | - |
Book Value |
61 M | -132 M | -193 M | -137 M | 97.7 M | 281 M | 105 M | -38.6 M | 30.5 M | 19.4 M | -6.93 M | 66.8 M | -42.4 M | 9.19 M | - |
Total Shareholders Equity |
61 M | -132 M | -193 M | -137 M | 97.7 M | 281 M | 105 M | -38.6 M | 31.8 M | 20.5 M | -6.21 M | 66.8 M | -97.1 M | -45.5 M | - |
All numbers in USD currency
Quarterly Balance Sheet Coherus BioSciences
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
459 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 498 K | - | - | 869 K | 875 K | 986 K | 952 K | 875 K | 73.7 M | 10.3 M | 73.3 M | 73.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
130 M | 187 M | 429 M | 320 M | 555 M | 581 M | 593 M | 759 M | 845 M | 823 M | 717 M | 644 M | 599 M | 618 M | 648 M | - | 581 M | 582 M | 611 M | 583 M | 566 M | 561 M | 561 M | 561 M | 561 M | 304 M | 304 M | 304 M | 304 M | 138 M | 138 M | 138 M | 138 M | 132 M | 132 M | 132 M | 132 M | 159 M | 159 M | 159 M | 159 M | 219 M | 219 M | 219 M | 219 M | 120 M | 120 M | 120 M | 120 M | 89.8 M | 89.8 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 669 K | 892 K | 892 K | 892 K | 892 K | 49.6 M | 49.6 M | 49.6 M | 49.6 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 14.3 M | 14.3 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.44 B | -1.42 B | -1.35 B | -1.31 B | -1.61 B | -1.55 B | -1.5 B | -1.49 B | -1.48 B | -1.58 B | -1.5 B | -1.46 B | -1.42 B | -1.34 B | -1.28 B | - | -1.15 B | -1.05 B | -1 B | -966 M | -936 M | -763 M | -763 M | -763 M | -763 M | -895 M | -895 M | -895 M | -895 M | -985 M | -985 M | -985 M | -985 M | -775 M | -775 M | -775 M | -775 M | -537 M | -537 M | -537 M | -537 M | -410 M | -410 M | -410 M | -410 M | -187 M | -187 M | -187 M | -187 M | -99.6 M | -99.6 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
191 M | 266 M | 517 M | 439 M | 371 M | 449 M | 505 M | 675 M | 764 M | 630 M | 584 M | 470 M | 402 M | 481 M | 551 M | - | 593 M | 679 M | 742 M | 740 M | 693 M | 842 M | 842 M | 842 M | 842 M | 409 M | 409 M | 409 M | 409 M | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 163 M | 163 M | 163 M | 163 M | 178 M | 178 M | 178 M | 178 M | 212 M | 212 M | 212 M | 212 M | 187 M | 187 M | 187 M | 187 M | 47.4 M | 47.4 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
82.9 M | 115 M | 103 M | 217 M | 82.4 M | 126 M | 98 M | 160 M | 260 M | 103 M | 80.3 M | 72.9 M | 16.1 M | 63.5 M | 287 M | 275 M | 326 M | 417 M | 361 M | 330 M | 259 M | 541 M | 541 M | 541 M | 541 M | 178 M | 178 M | 178 M | 178 M | 72.4 M | 72.4 M | 72.4 M | 72.4 M | 127 M | 127 M | 127 M | 127 M | 125 M | 125 M | 125 M | 125 M | 158 M | 158 M | 158 M | 158 M | 150 M | 150 M | 150 M | 150 M | 39.6 M | 39.6 M | - | - | 14.5 M | - | - | - | 7.68 M | - | - | - |
Book Value |
60.8 M | 78.6 M | 87.8 M | 120 M | -183 M | -132 M | -88 M | -84.1 M | -81.8 M | -193 M | -134 M | -175 M | -197 M | -137 M | -97.1 M | - | 12.6 M | 97.7 M | 131 M | 156 M | 128 M | 281 M | 281 M | 281 M | 281 M | 105 M | 105 M | 105 M | 105 M | -38.6 M | -38.6 M | -38.6 M | -38.6 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | -6.93 M | -6.93 M | -6.93 M | -6.93 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | -42.4 M | -42.4 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
60.8 M | 78.6 M | 87.8 M | 120 M | -183 M | -132 M | -88 M | -84.1 M | -81.8 M | -193 M | -134 M | -175 M | -197 M | -137 M | -97.1 M | -22.6 M | 12.6 M | 97.7 M | 131 M | 156 M | 128 M | 281 M | 281 M | 281 M | 281 M | 105 M | 105 M | 105 M | 105 M | -38.6 M | 12.4 M | 63.2 M | -1.79 M | 30.5 M | 31.8 M | 31.8 M | 31.8 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | -6.21 M | -6.21 M | -6.21 M | -6.21 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | -97.1 M | -97.1 M | - | - | -45.5 M | - | - | - | -2.31 M | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Coherus BioSciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
- | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M | Britain |